期刊
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
卷 21, 期 9, 页码 861-868出版社
TAYLOR & FRANCIS AS
DOI: 10.1080/14737159.2021.1952074
关键词
Chlamydia trachomatis; Molecular Diagnostics; Neisseria gonorrhoeae; Point of Care testing; Sexually Transmitted Diseases; binx health
类别
资金
- NIAID NIH HHS [UM1 AI068613, R01 AI138978, U01 AI068613] Funding Source: Medline
- NIBIB NIH HHS [U54 EB007958] Funding Source: Medline
The article discusses the urgent need for POC tests for CT and NG to control the STI epidemic and reduce transmission and sequelae. It introduces the binx io CT/NG assay as a new rapid molecular POC assay and highlights the importance of time to results and assay performance for this test.
Introduction: Point-of-care (POC) tests for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are urgently needed to control the STI epidemic in order to offer patients an immediate diagnoses and accurate treatment before they leave a clinical encounter and thus reduce transmission and sequelae. Nucleic acid amplification tests (NAATs) have increased sensitivity and specificity, but very few POC assays can provide results of such tests within the usual time of the patient visit. Areas covered: This review describes the technology and performance characteristics of the binx health io (R) [Boston, MA] (binx io) CT/NG assay, a new rapid molecular POC assay. The assay is compared to other available molecular POC tests. We also describe the importance of time to results and assay performance for this POC assay. Expert opinion: The binx io CT/NG assay offers the ability to incorporate the use of POC tests to identify and immediately treat chlamydia and gonococcal infections into the clinical visit, which will provide improved outcomes for patients. Additional implementation studies are needed to optimize the adoption of this new test.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据